Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata

Authors:

Abstract
Alopecia areata (AA) is a chronic autoimmune disease characterized by patchy or complete hair loss of any hair-bearing site that results from the collapse of hair follicle immune privilege.1 The oral Janus kinase (JAK) inhibitor baricitinib, administered at doses of 2 mg or 4 mg, once daily, demonstrated efficacy in achieving scalp hair regrowth over 52 weeks in 2 phase 3, double-blind, randomized clinical trials (BRAVE-AA1 and BRAVE-AA2) and has been approved for the treatment of adults with severe AA.2-4 More recently, the oral JAK3/TEC family inhibitor ritlecitinib has been approved for treating adults and adolescents with severe AA.5

This publication has 12 references indexed in Scilit: